Premium Healthcare Limited 03802128 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is residential care provision. Digita Accounts Production Advanced 6.30.9574.0 true true true true 03802128 2023-01-01 2023-12-31 03802128 2023-12-31 03802128 bus:Director1 2023-12-31 03802128 bus:Director10 2023-12-31 03802128 bus:Director11 2023-12-31 03802128 bus:Director2 2023-12-31 03802128 bus:Director3 2023-12-31 03802128 bus:Director4 2023-12-31 03802128 bus:Director9 2023-12-31 03802128 bus:OrdinaryShareClass1 2023-12-31 03802128 bus:OrdinaryShareClass2 2023-12-31 03802128 bus:Consolidated 2023-12-31 03802128 core:AcceleratedTaxDepreciationDeferredTax 2023-12-31 03802128 core:RevaluationPropertyDeferredTax 2023-12-31 03802128 core:RetainedEarningsAccumulatedLosses 2023-12-31 03802128 core:RevaluationReserve 2023-12-31 03802128 core:ShareCapital 2023-12-31 03802128 core:CurrentFinancialInstruments 2023-12-31 03802128 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 03802128 core:Non-currentFinancialInstruments 2023-12-31 03802128 core:Goodwill 2023-12-31 03802128 core:BetweenTwoFiveYears 2023-12-31 03802128 core:MoreThanFiveYears 2023-12-31 03802128 core:WithinOneYear 2023-12-31 03802128 core:FurnitureFittingsToolsEquipment 2023-12-31 03802128 core:LandBuildings 2023-12-31 03802128 bus:FRS102 2023-01-01 2023-12-31 03802128 bus:Audited 2023-01-01 2023-12-31 03802128 bus:FullAccounts 2023-01-01 2023-12-31 03802128 bus:RegisteredOffice 2023-01-01 2023-12-31 03802128 bus:Director1 2023-01-01 2023-12-31 03802128 bus:Director10 2023-01-01 2023-12-31 03802128 bus:Director11 2023-01-01 2023-12-31 03802128 bus:Director2 2023-01-01 2023-12-31 03802128 bus:Director3 2023-01-01 2023-12-31 03802128 bus:Director4 2023-01-01 2023-12-31 03802128 bus:Director9 2023-01-01 2023-12-31 03802128 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 03802128 bus:OrdinaryShareClass2 2023-01-01 2023-12-31 03802128 bus:Consolidated 2023-01-01 2023-12-31 03802128 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 03802128 core:FinancialGuarantees 2023-01-01 2023-12-31 03802128 core:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 03802128 core:RevaluationReserve 2023-01-01 2023-12-31 03802128 core:ShareCapital 2023-01-01 2023-12-31 03802128 core:LandBuildingsUnderOperatingLeases 2023-01-01 2023-12-31 03802128 core:PlantEquipmentUnderOperatingLeases 2023-01-01 2023-12-31 03802128 core:ComputerEquipment 2023-01-01 2023-12-31 03802128 core:FurnitureFittings 2023-01-01 2023-12-31 03802128 core:FurnitureFittingsToolsEquipment 2023-01-01 2023-12-31 03802128 core:LandBuildings 2023-01-01 2023-12-31 03802128 core:LeaseholdImprovements 2023-01-01 2023-12-31 03802128 core:MotorVehicles 2023-01-01 2023-12-31 03802128 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2023-01-01 2023-12-31 03802128 core:UKTax 2023-01-01 2023-12-31 03802128 countries:EnglandWales 2023-01-01 2023-12-31 03802128 2022-12-31 03802128 core:RetainedEarningsAccumulatedLosses 2022-12-31 03802128 core:RevaluationReserve 2022-12-31 03802128 core:ShareCapital 2022-12-31 03802128 core:Goodwill 2022-12-31 03802128 core:FurnitureFittingsToolsEquipment 2022-12-31 03802128 core:LandBuildings 2022-12-31 03802128 2022-01-01 2022-12-31 03802128 2022-12-31 03802128 bus:OrdinaryShareClass1 2022-12-31 03802128 bus:OrdinaryShareClass2 2022-12-31 03802128 core:AcceleratedTaxDepreciationDeferredTax 2022-12-31 03802128 core:RevaluationPropertyDeferredTax 2022-12-31 03802128 core:RetainedEarningsAccumulatedLosses 2022-12-31 03802128 core:RevaluationReserve 2022-12-31 03802128 core:ShareCapital 2022-12-31 03802128 core:CurrentFinancialInstruments core:WithinOneYear 2022-12-31 03802128 core:CurrentFinancialInstruments core:WithinOneYear core:RestatedAmount 2022-12-31 03802128 core:CurrentFinancialInstruments core:RestatedAmount 2022-12-31 03802128 core:Non-currentFinancialInstruments 2022-12-31 03802128 core:BetweenTwoFiveYears 2022-12-31 03802128 core:MoreThanFiveYears 2022-12-31 03802128 core:WithinOneYear 2022-12-31 03802128 core:FurnitureFittingsToolsEquipment 2022-12-31 03802128 core:LandBuildings 2022-12-31 03802128 core:RestatedAmount 2022-12-31 03802128 core:RetainedEarningsAccumulatedLosses 2022-01-01 2022-12-31 03802128 core:RevaluationReserve 2022-01-01 2022-12-31 03802128 core:ShareCapital 2022-01-01 2022-12-31 03802128 core:LandBuildingsUnderOperatingLeases 2022-01-01 2022-12-31 03802128 core:PlantEquipmentUnderOperatingLeases 2022-01-01 2022-12-31 03802128 core:UKTax 2022-01-01 2022-12-31 03802128 2021-12-31 03802128 core:RetainedEarningsAccumulatedLosses 2021-12-31 03802128 core:RevaluationReserve 2021-12-31 03802128 core:ShareCapital 2021-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 03802128

Premium Healthcare Limited

Annual Report and Financial Statements

for the Year Ended 31 December 2023

 

Premium Healthcare Limited

Contents

Company Information

1

Strategic Report

2

Directors' Report

3

Statement of Directors' Responsibilities

4

Independent Auditor's Report

5 to 7

Profit and Loss Account

8

Statement of Comprehensive Income

9

Balance Sheet

10

Statement of Changes in Equity

11

Notes to the Financial Statements

12 to 20

 

Premium Healthcare Limited

Company Information

Directors

A J Pancott

C Cannon-Brookes

A J Hibbard

Registered office

Hythe View
91 North Road
Hythe
Kent
CT21 5ET

Auditors

Hazlewoods LLP
Windsor House
Bayshill Road
Cheltenham
GL50 3AT

 

Premium Healthcare Limited

Strategic Report for the Year Ended 31 December 2023

The directors present their strategic report for the year ended 31 December 2023.

Principal activity

The principal activity of the company is residential care provision.

Fair review of the business

The results for the year, which are set out in the profit and loss account, show turnover of £5,353,029 (2022 - £4,705,479) and an operating profit of £194,415 (2022 - £505,352). At 31 December 2023, the company had net assets of £2,409,546 (2022 - £2,433.574). The directors consider the performance for the year and the financial position at the year end to be satisfactory.

Given the nature of the business, the company's directors are of the opinion that key performance indicators are important. The company uses a number of indicators to monitor and improve development, performance or the position of the business. Indicators are reviewed and altered to meet changes both in the internal and external environments. The directors do not consider the inclusion of an analysis using key performance indicators to be necessary to assist users of the financial statements in their understanding of the financial performance or position of the company.

Principal risks and uncertainties

The management of the business and the execution of the company's strategy are subject to a number of risks. The key business risks and uncertainties affecting the company are considered to relate to ongoing compliance with current and future legislation affecting the sector.

Approved by the Board on 19 September 2024 and signed on its behalf by:


A J Pancott
Director

 

Premium Healthcare Limited

Directors' Report for the Year Ended 31 December 2023

The directors present their report and the financial statements for the year ended 31 December 2023.

Directors of the company

The directors who held office during the year were as follows:

S L Grant (ceased 31 January 2023)

S J Quinlan (ceased 28 March 2024)

P W Richards (ceased 7 February 2023)

R E Saunders (ceased 28 March 2024)

A J Pancott (appointed 7 February 2023)

The following directors were appointed after the year end:

C Cannon-Brookes (appointed 28 March 2024)

A J Hibbard (appointed 28 March 2024)

Financial instruments

Objectives and policies

The board constantly monitors the company's trading results and revise projections as appropriate to ensure that the company can meet its future obligations as they fall due.

Price risk, credit risk, liquidity risk and cash flow risk

The company is exposed to the usual credit and cash flow risks associated with selling on credit and manages this through credit control procedures.

The company's financial instruments are not considered to be subject to price or liquidity risk.

The company has sufficient resources available and the directors have prepared forecasts for the next 12 months that indicate that this will continue to be the case and that these cash flows will be sufficient for the company to meet its financing commitments as they fall due. The directors therefore have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and have continued to adopt the going concern basis in preparing the financial statements.

Future developments

The external environment is expected to remain competitive going forward, however the directors remain confident that the company will continue to improve its current level of performance in the future and will continue to trade as a going concern.

Disclosure of information to the auditors

Each director has taken steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditors are unaware.

Reappointment of auditors

Hazlewoods LLP have expressed their willingness to continue in office.

Approved by the Board on 19 September 2024 and signed on its behalf by:


A J Pancott
Director

 

Premium Healthcare Limited

Statement of Directors' Responsibilities

The directors are responsible for preparing the Strategic Report, Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

select suitable accounting policies and apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

state whether applicable UK Accounting Standards has been followed, subject to any material departures disclosed and explained in the financial statements; and

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Premium Healthcare Limited

Independent Auditor's Report to the Members of Premium Healthcare Limited

Opinion

We have audited the financial statements of Premium Healthcare Limited (the 'company') for the year ended 31 December 2023, which comprise the Profit and Loss Account, Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the company's affairs as at 31 December 2023 and of its profit for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

 

Premium Healthcare Limited

Independent Auditor's Report to the Members of Premium Healthcare Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

the Strategic Report and Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

the financial statements are not in agreement with the accounting records and returns; or

certain disclosures of directors' remuneration specified by law are not made; or

we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We considered the nature of the company’s industry and its control environment and reviewed the company’s documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.

We obtained an understanding of the legal and regulatory framework that the company operates in and identified the key laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements, including the UK Companies Act and tax legislation, and, those that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company’s ability to operate or to avoid a material penalty.

We discussed among the audit engagement team regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

 

Premium Healthcare Limited

Independent Auditor's Report to the Members of Premium Healthcare Limited

In common with all audits conducted in accordance with ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override of controls. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, our procedures to respond to the risks identified included the following:

reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;

performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatements due to fraud;

enquiring of management concerning actual and potential litigation and claims and instances of non-compliance with laws and regulations; and

reading minutes of meetings of those charged with governance.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities is available on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.





Simon Worsley (Senior Statutory Auditor)
For and on behalf of Hazlewoods LLP, Statutory Auditor

Windsor House
Bayshill Road
Cheltenham
GL50 3AT

19 September 2024

 

Premium Healthcare Limited

Profit and Loss Account for the Year Ended 31 December 2023

Note

2023
£

2022
£

Turnover

3

5,353,029

4,705,479

Cost of sales

 

(3,400,486)

(2,857,599)

Gross profit

 

1,952,543

1,847,880

Administrative expenses

 

(1,653,555)

(1,234,542)

Exceptional items

5

(104,573)

(107,986)

Operating profit

4

194,415

505,352

Other interest receivable and similar income

6

8,135

503

Interest payable and similar charges

7

-

(31,616)

Profit before tax

 

202,550

474,239

Taxation

11

(72,340)

(35,625)

Profit for the financial year

 

130,210

438,614

The above results were derived from continuing operations.

The company has no other comprehensive income for the year.

 

Premium Healthcare Limited

Statement of Comprehensive Income for the Year Ended 31 December 2023

2023
£

2022
£

Profit for the year

130,210

438,614

Surplus leasehold revaluation

-

1,717,500

Total comprehensive income for the year

130,210

2,156,114

 

Premium Healthcare Limited

(Registration number: 03802128)
Balance Sheet as at 31 December 2023

Note

2023
 £

(As restated)
2022
 £

Fixed assets

 

Intangible assets

12

-

-

Tangible assets

13

2,971,305

2,638,295

 

2,971,305

2,638,295

Current assets

 

Debtors: Amounts falling due within one year

14

1,419,578

1,210,736

Debtors: Amounts falling due after more than one year

14

1,763,200

1,797,611

Cash at bank and in hand

 

277,672

407,120

 

3,460,450

3,415,467

Creditors: Amounts falling due within one year

15

(3,368,079)

(3,048,203)

Net current assets

 

92,371

367,264

Total assets less current liabilities

 

3,063,676

3,005,559

Provisions for liabilities

11

(654,130)

(571,985)

Net assets

 

2,409,546

2,433,574

Capital and reserves

 

Called up share capital

17

1,000

1,000

Revaluation reserve

1,646,675

1,717,500

Profit and loss account

761,871

715,074

Total equity

 

2,409,546

2,433,574

Approved and authorised by the Board on 19 September 2024 and signed on its behalf by:
 


A J Pancott
Director

 

Premium Healthcare Limited

Statement of Changes in Equity for the Year Ended 31 December 2023

Share capital
£

Revaluation reserve
£

Profit and loss account
£

Total
£

At 1 January 2023

1,000

1,717,500

715,074

2,433,574

Profit for the year

-

-

130,210

130,210

Dividends

-

-

(154,238)

(154,238)

Transfers

-

(70,825)

70,825

-

At 31 December 2023

1,000

1,646,675

761,871

2,409,546

Share capital
£

Revaluation reserve
£

Profit and loss account
£

Total
£

At 1 January 2022

1,000

-

864,000

865,000

Profit for the year

-

-

438,614

438,614

Other comprehensive income

-

1,717,500

-

1,717,500

Dividends

-

-

(587,540)

(587,540)

At 31 December 2022

1,000

1,717,500

715,074

2,433,574

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Hythe View
91 North Road
Hythe
Kent
CT21 5ET

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland and the Companies Act 2006'.

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Summary of disclosure exemptions

The company has not presented a cash flow statement on the grounds that the company is a wholly owned subsidiary and a group cash flow statement is included in the financial statements of the ultimate parent company.

Name of parent of group

These financial statements are consolidated in the financial statements of Hythe Care Homes Limited.

The financial statements of Hythe Care Homes Limited may be obtained from Companies House.

Going concern

After reviewing the company’s current forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Prior period errors

During the year it was identified that a related party company had paid a rent deposit on behalf of the company during the previous year. This deposit of £710,000 has now been recognised in other debtors with a corresponding liability of £710,000 payable to the related party company. This prior year adjustment has no impact on the prior year profit or reserves.

Judgements and estimation uncertainty

These financial statements do not contain any significant judgements or estimation uncertainty.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities.

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

Government grants

Government grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets with the exception of leasehold properties are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Leasehold property is valued at fair value at the balance sheet date. The fair value is based on the valuation by a professional valuer.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Leasehold property

Over the term of the lease

Improvements to property

10% on cost

Fixtures and fittings

25% reducing balance

Motor vehicles

25% reducing balance

Computer equipment

33% on cost

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.

Negative goodwill arising on an acquisition is recognised on the face of the balance sheet on the acquisition date and subsequently the excess up to the fair value of non-monetary assets acquired is recognised in profit or loss in the periods in which the non-monetary assets are recovered.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

Trade debtors

Trade debtors are amounts due from customers for services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

Financial instruments (continued)

Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

 

3

Turnover

The analysis of the company's turnover for the year by class of business is as follows:

2023
£

2022
£

Rendering of care services

5,352,939

4,623,012

Grant income

90

82,467

5,353,029

4,705,479

The total turnover of the company has been derived from its principal activity wholly undertaken in the United Kingdom.

 

4

Operating profit

Arrived at after charging/(crediting)

2023
£

2022
£

Depreciation expense

215,746

103,189

Operating lease expense - property

753,659

562,353

Operating lease expense - plant and machinery

2,772

2,344

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

 

5

Exceptional items

2023
 £

2022
 £

Exceptional expenses

104,573

107,986

Exceptional items in the current year consist of professional and administrative costs.

Exceptional items in the prior year consisted of tendering costs, irrecoverable VAT and administrative expenses.

 

6

Other interest receivable and similar income

2023
£

2022
£

Interest income on bank deposits

8,135

503

 

7

Interest payable and similar expenses

2023
£

2022
£

Interest expense on other finance liabilities

-

31,616

 

8

Staff costs

The aggregate payroll costs (including directors' remuneration) were as follows:

2023
£

2022
£

Wages and salaries

2,501,066

2,179,824

Social security costs

193,489

174,679

Pension costs, defined contribution scheme

45,314

39,885

2,739,869

2,394,388

The average number of persons employed by the company (including directors) during the year, analysed by category was as follows:

2023
No.

2022
No.

Care staff

128

118

 

9

Directors' remuneration

Directors' remuneration has been borne by a related party.

 

10

Auditors' remuneration

2023
£

2022
£

Audit of the financial statements

4,750

9,000

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

 

11

Taxation

Tax charged/(credited) in the profit and loss account

2023
£

2022
£

Current taxation

UK corporation tax

29,401

35,625

UK corporation tax adjustment to prior periods

(39,206)

-

(9,805)

35,625

Deferred taxation

Arising from origination and reversal of timing differences

82,145

-

Tax expense in the income statement

72,340

35,625

The tax on profit before tax for the year is the same as the standard rate of corporation tax in the UK (2022 - the same as the standard rate of corporation tax in the UK) of 23.5% (2022 - 19%).

The differences are reconciled below:

2023
£

2022
£

Profit before tax

202,550

474,239

Corporation tax at standard rate

47,599

90,105

Effect of expense not deductible in determining taxable profit (tax loss)

17,101

(4,759)

Deferred tax expense relating to changes in tax rates or laws

3,222

-

Decrease in UK and foreign current tax from adjustment for prior periods

(39,206)

-

Tax increase/(decrease) from effect of capital allowances and depreciation

71,206

(10,773)

Tax decrease arising from group relief

(27,582)

(38,948)

Total tax charge

72,340

35,625

Deferred tax

Deferred tax assets and liabilities

2023

Liability
£

Difference between accumulated depreciation and capital allowances

105,238

Revaluation of leasehold contracts

548,892

654,130

2022

Liability
£

Difference between accumulated depreciation and capital allowances

(515)

Revaluation of leasehold contracts

572,500

571,985

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

 

12

Intangible assets

Goodwill
 £

Cost

At 1 January 2023 and at 31 December 2023

95,000

Amortisation

At 1 January 2023 and at 31 December 2023

95,000

Carrying amount

At 31 December 2022 and at 31 December 2023

-

 

13

Tangible assets

Leasehold property
£

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 January 2023

2,519,736

1,178,754

3,698,490

Additions

427,255

121,501

548,756

At 31 December 2023

2,946,991

1,300,255

4,247,246

Depreciation

At 1 January 2023

105,826

954,369

1,060,195

Charge for the year

127,833

87,913

215,746

At 31 December 2023

233,659

1,042,282

1,275,941

Carrying amount

At 31 December 2023

2,713,332

257,973

2,971,305

At 31 December 2022

2,413,910

224,385

2,638,295

 

14

Debtors

2023
 £

(As restated)
2022
 £

Trade debtors

416,181

310,760

Other debtors

719,917

729,402

Prepayments

283,480

170,574

Amounts owed by group undertakings

1,763,200

1,797,611

 

3,182,778

3,008,347

Less non-current portion

(1,763,200)

(1,797,611)

Total current trade and other debtors

1,419,578

1,210,736

Details of non-current trade and other debtors

£1,763,200 (2022 - £1,797,611) of amounts owed by group undertakings is classified as non current.

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

 

15

Creditors

2023
 £

(As restated)
2022
 £

Due within one year

Trade creditors

107,379

52,672

Amounts due to group undertakings

2,674,216

2,378,026

Social security and other taxes

42,125

93,520

Outstanding defined contribution pension costs

28,688

27,402

Other creditors

62,585

179,042

Accrued expenses

172,973

109,001

Corporation tax liability

29,401

72,589

Deferred income

250,712

135,951

3,368,079

3,048,203

 

16

Pension and other schemes

Defined contribution pension scheme

The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £45,314 (2022 - £39,885).

Contributions totalling £28,688 (2022 - £27,402) were payable to the scheme at the end of the year and are included in creditors.

 

17

Share capital

Allotted, called up and fully paid shares

 

2023

2022

 

No.

£

No.

£

Ordinary shares of £1 each

500

500

500

500

Ordinary A shares of £1 each

500

500

500

500

 

1,000

1,000

1,000

1,000

Rights, preferences and restrictions

The different classes of share referred to above carry separate rights to dividends, but in all other significant respects rank pari passu.

 

18

Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

2023
£

2022
£

Not later than one year

745,348

710,312

Later than one year and not later than five years

2,953,600

2,840,000

Later than five years

13,485,409

13,678,685

17,184,357

17,228,997

 

Premium Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 December 2023

 

19

Dividends

2023
 £

2022
 £

Dividends paid

154,238

587,540

 

20

Contingent liabilities

Post year end as part of the change in ownership of the company, the company became party to a cross guarantee arrangement in respect of loans owed by its new ultimate parent company Willow DC Topco Limited, up to an agreed amount.

 

21

Related party transactions

Summary of transactions with key management

Key management personnel are considered to be the directors of the company and key management personnel compensation is disclosed in note 9 to the financial statements.

 

22

Parent and ultimate parent undertaking

The company's immediate parent is Hythe Care Homes Limited, incorporated in England and Wales.

 The ultimate parent was Integrum Care Opco Limited, incorporated in Jersey. Following a post year end acquisition on 28 March 2024, the ultimate parent company is now Willow DC Topco Ltd, incorporated in England and Wales.
 

Following a post year end acquisition on 28 March 2024, the ultimate parent company is now Willow DC Topco Ltd, incorporated in England and Wales.